Responsable/s del laboratorio
Head of lab
intro
Nuestras principales líneas de investigación están dirigidas a la caracterización de la migración y diferenciación de células del sistema inmune, y a la identificación de mecanismos moleculares implicados en resistencia a terapias de células tumorales
Miembros
| Joaquín Teixidó Calvo |
| Ana Paula de Jesus Santos |
| Nohemí Arellano Sánchez |
| Marta Hurtado Borras |
| Yaiza Rodriguez Garcia |
| Valeria Burdiel Herencia |
Publicaciones seleccionadas
Sevilla-Movilla S, Arellano-Sánchez N, Martínez-Moreno M, Gajate C, Sánchez-Vencells A, Vitores Valcárcel L, Agirre X, Valeri A, Martínez-López J, Prósper F,Mollinedo F and Teixidó J. [2020]. Upregulated expression and function of the a4b1 integrin in multiple myeloma cells resistant to bortezomib. J. Pathol. 252: 29-40
Benito-Jardón L, Díaz-Martínez M, Arellano-Sánchez N, Vaquero-Morales P, Esparis-Ogando A and Teixidó J [2019]. Resistance to MAPK inhibitors in melanoma involves activation of the IGF-1R-MEK5-Erk5 pathway. Cancer Res. 79(9): 2244-2256
Redondo-Muñoz J, García-Pardo A and Teixidó J [2019]. Molecular players in hematological tumor cell trafficking. Frontiers in Immunol. 10:156
Teixidó J, Martínez-Moreno M, Díaz-Martínez M and Sevilla-Movilla S. [2018]. The good and bad faces of the CXCR4 chemokine receptor. Internat. J. Biochem. Cell Biol. 95: 121-131
Díaz-Martínez M, Benito-Jardón L, Alonso L, Koetz-Ploch L, Hernando E, Teixido J. [2018]. miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma. Cancer Research, 78: 1017-1030.
M Martínez-Moreno, M Leiva, N Aguilera-Montilla, S Sevilla-Movilla, S I de Val, N Arellano-Sánchez, N C Gutiérrez, R Maldonado, J Martínez-López, I Buño, J A García-Marco, P Sánchez-Mateos, A Hidalgo, A García-Pardo and J Teixidó [2016]. In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins. 2016. Leukemia, 30, 861-872
Gutiérrez-González A, Martínez-Moreno M, Samaniego R, Arellano-Sánchez N, Salinas-Muñoz L, Relloso M, Valeri A, Martínez-López J, Corbí ÁL, Hidalgo A, García-Pardo Á, Teixidó J, Sánchez-Mateos P. [2016]. Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood. 128: 2241-2252
Sosa-Costa A, Isern de Val S, Sevilla-Movilla S, Borgman KJ, Manzo C, Teixidó J, Garcia-Parajo MF. [2016]. Lateral Mobility and Nanoscale Spatial Arrangement of Chemokine-activated α4β1 Integrins on T Cells. J Biol Chem. 291: 21053-21062
Dios-Esponera A, Isern de Val S, Sevilla-Movilla S, García-Verdugo R, García-Bernal D, Arellano-Sánchez N, Cabañas C, Teixidó J. [2015]. Positive and negative regulation by SLP-76/ADAP and Pyk2 of chemokine-stimulated T lymphocyte adhesion mediated by integrin α4β1. Mol Biol Cell. 2015 Jul 22. pii: mbc.E14-07-1246. PMID: 26202465
García-Bernal D, Redondo-Muñoz J, Dios-Esponera A, Chèvre R, Bailón E, Garayoa M, Arellano-Sánchez N, Gutiérrez NC, Hidalgo A, García-Pardo A, Teixidó J [2013]. Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function. J Pathol 229: 36-48
Fondos
- Characterization of molecular mechanisms involved in thymocyte development and in melanoma cell resistance to MAP quinase inhibitors.
PID2020-116291RB-I00. 2021-2024. PI, Joaquin Teixidó
- Characterization of molecular mechanisms involved in migration, survival and resistance to chemotherapy in multiple myeloma and melanoma.
SAF2017-85146-R: 2018-2020. PI: Joaquin Teixidó
- Imaging, genomics and proteomics analyses of B cell hematological tumor progression
S2010/BMD-2314. Biomedicina. Comunidad de Madrid. 2012-2016. PI: Joaquin Teixido